Pfizer Ranked As Leading Company In Asia For Covid-19 Response And Patient-Centric Approach

Asian patient groups have placed the pharmaceutical company first for corporate reputation in Asia.

SINGAPORE, August 26 – Pfizer has been ranked first in its Covid-19 response, patient centricity, patient safety, and producing innovative, high-quality products in the 2021 Corporate Reputation of Pharma survey by patient groups across the Asia-Pacific region.

Overall, the company is ranked second for its corporate reputation across Asian countries. 

Pfizer moved up in the survey rankings from fourth place to occupy the top ranking in terms of patient groups working with Pfizer, representing a significant increase in rankings from 2020. 

This survey, conducted by United Kingdom-based PatientView, measures various aspects of pharmaceutical companies’ performances and corporate reputations from a patient perspective.

Patient groups responding to this survey work across therapeutic areas and are uniquely positioned to comment on the pharmaceutical industry’s performance during the Covid-19 pandemic. 

Opinions from 300 patient groups in 10 countries on the performance of the pharmaceutical industry were collected in 2021. These Asian patient groups have collectively been in communication with nearly 2.7 million Asian patients in 2021. A total of 31 pharmaceutical companies were assessed by these groups in the 2021 Asia edition of the annual survey. 

Asian patient groups familiar with and/or working with Pfizer concluded that the company has significantly improved its scores across all indicators of corporate reputation in 2021.

Pharmaceutical companies’ performances at creating and conveying vaccines in response to the Covid-19 pandemic convinced most of the patient groups of the company’s effectiveness in both innovation and ability, delivering products that truly benefit patients.

“Patients are our north star. From the earliest stage of drug development to the final approval and use of our medicines and vaccines, our purpose is breakthroughs that change patients’ lives. We work with, and for, patients, advocates, and caregivers to meet the evolving needs of patients everywhere,” said Anil Argilla, president, Emerging Markets Asia, Pfizer Biopharmaceuticals Group. 

The 2021 Corporate Reputation of Pharma survey can be accessed here.

You may also like